Engineered Immune Cells for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adoptive T cell therapy for cancer faces challenges such as cellular exhaustion, long preparation times, and ineffective compositions of engineered cells, particularly in the context of immunotherapy where ex vivo expansion of tumor-specific T cells is lengthy and inefficient.
Innovation Solution
The method involves infusing engineered immune cells expressing chimeric antigen receptors (CAR) or engineered T cell receptors (TCR) with a higher abundance of central memory T cells, reduced exhaustion markers like PD1 and LAG3, and shorter ex vivo expansion times, typically less than 2 weeks, to enhance their immune regulatory capabilities and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ex vivo expansion of tumor-specific T cells is performed to increase the number of T cells, then the quantity of immune cells is improved, but the preparation time increases and cellular exhaustion occurs
Solution Approach 1:
The patent applies preliminary action by performing ex vivo expansion of T cells before infusion into patients. T cells are expanded in advance under controlled laboratory conditions to achieve sufficient quantity, then infused into patients who receive supportive care during the expansion period. This separates the time-consuming expansion process from the treatment delivery, allowing parallel progression of both activities.
2Quantity of substance
If ex vivo expansion of T cells is performed to increase the number of T cells, then the quantity of immune cells is improved, but cellular exhaustion increases
Solution Approach 1:
The patent applies local quality by creating different functional subsets of T cells with specialized properties. It generates tumor-specific T cells with high affinity for tumor antigens through selective pressure and cytokine treatment, while also producing regulatory T cells that modulate the immune response. This differentiation ensures that T cells maintain functionality and reduce exhaustion by dividing labor among specialized subsets rather than relying on a single homogeneous population.
3Reliability
If traditional adoptive T cell therapy methods are used, then the therapeutic approach is established, but the composition of engineered cells is ineffective
Solution Approach 1:
The patent applies parameter changes by systematically modifying T cell characteristics through controlled exposure to specific cytokines (IL-2, IL-15, IL-21) and tumor antigens during ex vivo expansion. It adjusts parameters such as cytokine concentration, exposure duration, and antigen specificity to optimize T cell functionality. This results in engineered cells with enhanced proliferative capacity, reduced exhaustion markers, and improved anti-tumor activity compared to traditional methods.
Data Source
AI summary
The present disclosure provides compositions and methods for engineered cellular compositions and methods of immunotherapy utilizing the same. Compositions of the present disclosure for immune cell regulation comprise a chimeric antigen receptor polypeptide, a T cell receptor polypeptide, and combinations thereof.